The 23 references in paper T. Ospel'nikova P., O. Morozova V., E. Isaeva I., G. Osipova L., L. Kolodyazhnaya V., E. Pritchina N., M. Smirnova Yu., S. Andreeva A., V. Pankratova N., F. Ershov I., A. Chuchalin G., Т. Оспельникова П., О. Морозова В., Е. Исаева И., Г. Осипова Л., Л. Колодяжная В., Е. Притчина Н., М. Смирнова Ю., С. Андреева А., В. Панкратова Н., Ф. Ершов И., А. Чучалин Г. (2015) “Респираторные вирусы и бактерии, антитела и цитокины у больных с фенотипом "бронхиальная астма и хроническая обструктивная болезнь легких" // Respiratory viruses and bacteria, antibodies and cytokines in patients with bronchial asthma and chronic obstructive pulmonary disease phenotype” / spz:neicon:pulmonology:y:2014:i:5:p:46-51

1
Postma D.S., Reddel H.K., ten Hacken N.H., van den Berge M. Asthma and chronic obstructive pulmonary disease: similarities and differences. Clin. Chest Med. 2014; 35 (1): 143–156.
(check this in PDF content)
2
Louie S., Zeki A.A., Schivo M. et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert. Rev. Clin. Pharmacol. 2013; 6 (2): 197–219.
(check this in PDF content)
3
Nakawah M.O., Hawkins C., Barbandi F. Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome.J. Am. Board Fam. Med. 2013; 26 (4): 470–477.
(check this in PDF content)
4
Miravitlles M., Soler-Cataluna J.J., Calle M. et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Aten. Primaria. 2012; 44: 425–437.
(check this in PDF content)
5
Mallia P., Footitt J., Sotero R. et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186 (11): 1117–1124.
(check this in PDF content)
6
Seemungal T., Harber-Owen R., Bhowmik A. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 2001; 164 (9): 1618–1623.
(check this in PDF content)
7
Warg S.P., Grayston J.T. Immunological relationship between genital TRIC, lymphogranulomavenerum and related organisms in a new microtiter indirect immunofluorescence test. Am. J. Ophthalmol. 1970; 70 (3): 367–374.
(check this in PDF content)
8
Лабинская А.С., Блинкова Л.П., Eщина А.С. Частная медицинская микробиология с техникой микробиологических исследований. М.: Медицина; 2005; 432–461.
(check this in PDF content)
9
Ершов Ф.И. Система интерферона в норме и при патологии.М.: Медицина; 1996: 147–155. Рис. 2. Функциональная способность лейкоцитов крови у больных БА + ХОБЛ к продукции IFN-αи -γ(p≤0,05): по оси абсцисс: а– IFN-α; б– IFN-γ; по оси ординат: значения продукции, ед. / мл Примечание: Голубые столбцы– продукция IFN клетками практически здоровых добровольцев; Красные столбцы– продукция IFN клетками больных БА + ХОБЛ. Рис. 1. Детекция РНК цитокинов и противовирусных белков в мокроте больных БА + ХОБЛ методом ОТ-ПЦР-РВ с гибридизационно-флюоресцентной детекцией: а– IFN-α; б– IFN-β; в– IFN-λ; г – MxA; д– частота детекции РНК а аб бд вг Оспельникова Т.П. и др. Респираторные вирусы и бактерии, антитела и цитокины у больных с фенотипом "БА и ХОБЛ"
(check this in PDF content)
10
Лакин Г.Ф. Биометрия.М.: Высшая школа; 1980.
(check this in PDF content)
11
Johnston S. Experimental models of rhinovirus-induced exacerbations of asthma: where to know? Am. J. Respir. Crit. Care Med. 2003; 168: 1145–1146.
(check this in PDF content)
12
Juntti H., Kokkonen J., Dunder T. et al. Association of an early respiratory syncytial virus infection and atopic allergy. Allergy. 2003; 58: 878–884.
(check this in PDF content)
13
Iikura K., Katsunuma T., Saika S. et al. Peripheral blood mononuclear cells from patients with bronchial asthma show impaired innate immune responses to rhinovirus in vitro.Int. Arch. Allergy Immunol. 2011; 155 (Suppl. 1): 27–33.
(check this in PDF content)
14
Message S.D., Johnston S.L. Host defense function of the airway epithelium in health and disease: clinical background. J. Leukocyte Biol. 2004; 75: 5–17.
(check this in PDF content)
15
Message S.D., Johnston S.L. Viruses in asthma.Br. Med. Bull. 2002; 61: 29–43.
(check this in PDF content)
16
Forster S. Interferon signatures in immune disorders and disease.Immunol. Cell. Biol. 2012; 90 (5): 520–527.
(check this in PDF content)
17
Mangan N.E., Fung K.Y. Type I interferons in regulation of mucosal immunity.Immunol. Cell. Biol. 2012; 90 (5): 510–519.
(check this in PDF content)
18
Weerd N.A., Nguyen T. The interferons and their receptors – distribution and regulation. Immunol. Cell. Biol. 2012; 90 (5): 483–491.
(check this in PDF content)
19
Gallagher G., Megjugorac N.J., Yu R.Y. et al. The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J. Interferon Cytokine Res.
(check this in PDF content)
20
0; 30 (8): 603–615. 20. Haller O., Kochs G. Human MxA protein: an interferoninduced dynamin-like GTPase with broad antiviral activity. J. Interferon Cytokine Res. 2011; 31 (1): 79–87.
(check this in PDF content)
21
Cakebread J.A., Xu Y., Grainge C. et al. Exogenous IFN-β has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus.J. Allergy Clin. Immunol. 2011; 127 (5): 1148–1154.
(check this in PDF content)
22
Оспельникова Т.П., Конищева А.В., Мазурина С.А. и др. Оценка системы интерферона и основных цитокинов у больных бронхиальной астмой. Журнал микробиологии, эпидемиологии и иммунобиологии. 2012; 1: 35–41.
(check this in PDF content)
23
Contoli M., Message S.D., Laza-Stanca V. et al. Role of deficient type III interferon-αproduction in asthma exacerbations. Nat. Med. 2006; 12: 1023–1026. Поступила 19.06.14 УДК [616.248-06:616.24-036.12]-092
(check this in PDF content)